{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-015955","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.272341+00:00","generated_at":"2026-05-21T23:49:58.916635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UroGen Pharma Q1 2025: JELMYTO revenue $20.3M, net loss widens to $43.8M; UGN-102 PDUFA June 13","bullets":["JELMYTO net sales $20.3M (+8% YoY); underlying demand grew 12%.","Net loss of $43.8M ($0.92 per share) vs $32.3M ($0.87) in Q1 2024.","Cash and marketable securities $200.4M; FY2025 JELMYTO revenue guidance unchanged at $94–$98M.","UGN-102 NDA under FDA review; PDUFA target action date June 13, 2025; ODAC meeting May 21.","UGN-501 acquisition from IconOVir expensed; UGN-103 Phase 3 UTOPIA trial enrollment to complete mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-015955","json":"https://secwatch.observer/filing/0001437749-25-015955.json","markdown":"https://secwatch.observer/filing/0001437749-25-015955.md","text":"https://secwatch.observer/filing/0001437749-25-015955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/0001437749-25-015955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/urgn20250428_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:49:58.916635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}